Duality S.A. Stock

Equities

DUA

PLDLITY00010

End-of-day quote Warsaw S.E. Other stock markets 06:00:00 2024-05-07 pm EDT			5-day change	1st Jan Change
1.76 ^PLN	+3.53%		+11.39%	+18.92%

Mar. 20	Duality S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 11	BioNTech to Present Clinical Data Updates on Cancer Vaccine Candidates	MT

on all our subscriptions*

Take advantage of the offer

* See conditions on site

Financials

Sales 2022	2.14M 534K	Sales 2023	5.64M 1.41M	Capitalization	5.92M 1.48M
Net income 2022	- 0	Net income 2023	-3M -749K	EV / Sales 2022	5.54 x
Net cash position 2022	908K 227K	Net cash position 2023	66.53K 16.62K	EV / Sales 2023	1.04 x
P/E ratio 2022	24.6 x	P/E ratio 2023	-1.64 x	Employees	2
Yield 2022 *	-	Yield 2023	-	Free-Float	0%

More Fundamentals * Assessed data

Chart Duality S.A.

Duration

Period

Style

Latest news about Duality S.A.

Duality S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20	CI
BioNTech to Present Clinical Data Updates on Cancer Vaccine Candidates	Mar. 11	MT
Tod's CEO says he has no plans to sell 'family business'	Feb. 23	RE
BioNTech, Duality Biologics Obtain FDA Fast Track Designation for Ovarian Cancer Therapy Candidate	Jan. 31	MT
BioNTech's Cancer Therapy Candidate Obtains Fast-track Designation from US FDA	Jan. 31	MT
BioNTech, Duality Biologics Initiate Phase 3 Trial of Breast Cancer Drug	Jan. 22	MT
BioNTech Begins Late-stage Study for Metastatic Breast Cancer Therapy Candidate	Jan. 22	MT
BioNTech challenges AstraZeneca with breast cancer precision drug trial	Jan. 22	RE
BioNTech, Duality Biologics Get US FDA Breakthrough Therapy Designation for Uterine Cancer Drug Candidate	Dec. 21	MT
Duality S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Australia's Albanese to highlight trade on China visit as ties warm	Nov. 03	RE
Duality S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Introducing Janus, the exotic 'two-faced' white dwarf star	23-07-21	RE
HBM Holdings, Beigene Sign License Deal for Antibody-Drug Conjugate Program; HBM Shares Soar 20%	23-07-14	MT
Duality S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI

News in other languages on Duality S.A.

LATE BRIEFING - Unternehmen und Märkte	Jan. 31
Biontech treibt mit Partner Entwicklung von Krebsmittel voran	Jan. 22
LATE BRIEFING - Unternehmen und Märkte -2-	Dec. 21
LATE BRIEFING - Unternehmen und Märkte	23-04-03

Quotes and Performance

1 day	+3.53%
1 week	+11.39%
Current month	+11.39%
1 month	+15.41%
3 months	-9.04%
6 months	+7.32%
Current year	+18.92%

Highs and lows

1 week

1.59

2.02

1 month

1.23

2.02

Current year

1.23

2.49

1 year

1.23

5.16

3 years

1.23

7.78

5 years

1.23

10.30

10 years

1.23

10.30

Managers and Directors - Duality S.A.

Managers	Title	Age	Since
Michal Witold Szewerniak FOU	Founder	37	17-11-10
Tomasz Strzalkowski CEO	Chief Executive Officer	48	17-12-10
Michal Szmidt PRN	Corporate Officer/Principal	-	-

Members of the board	Title	Age	Since
Grzegorz Arkadiusz Czarnecki BRD	Director/Board Member	49	16-12-31
Marcin Kostrzewa CHM	Chairman	29	19-02-28
Michal Witold Szewerniak FOU	Founder	37	17-11-10

Quotes

Date	Price	Change	Volume
24-05-08	1.76	+3.53%	41,179
24-05-07	1.7	+6.58%	14,383
24-05-06	1.595	-5.62%	12,214
24-05-02	1.69	+6.96%	23,573
24-04-30	1.58	+9.34%	24,098

End-of-day quote Warsaw S.E., May 07, 2024

Company Profile

Sector

-

More about the company

Income Statement Evolution

More financial data

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW